-
Publication Venue For
-
A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma..
8:e384-e386.
2021
-
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial..
8:e254-e266.
2021
-
Tackling adherence in sickle cell disease with mHealth..
7:e713-e714.
2020
-
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts..
7:e601-e612.
2020
-
Coagulation abnormalities and thrombosis in patients with COVID-19..
7:e438-e440.
2020
-
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial..
7:e490-e497.
2020
-
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial..
6:e419-e428.
2019
-
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial..
5:e532-e542.
2018
-
Automated typing of red blood cell and platelet antigens: a whole-genome sequencing study..
5:e241-e251.
2018
-
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial..
4:e431-e442.
2017
-
Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis..
4:e325-e333.
2017
-
High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan..
4:e283-e292.
2017
-
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials..
4:e176-e182.
2017
-
Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial..
3:e407-e414.
2016
-
Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis..
3:e276-e283.
2016
-
Edoxaban in the secondary prevention of VTE..
3:e208-e209.
2016
-
Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis..
3:e45-e52.
2016
-
Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study..
2:e367-e375.
2015
-
Symptom burden of haematological malignancies as death approaches in a community palliative care service: a retrospective cohort study of a consecutive case series..
2:e334-e338.
2015
-
Effect of red blood cell variants on childhood malaria in Mali: a prospective cohort study..
2:e140-e149.
2015
-
Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis..
2:e66-e74.
2015